Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 5/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31162543 | 0.90 | NR1H2 (0.49) | NR1H2GLAPOLBGAATSHR | |
| SCHEMBL26460616 | 0.85 | GAA (0.55) | NR1H2GLAPOLBGAATSHR | |
| SCHEMBL13991110 | 0.84 | NR1H2 (0.47) | NR1H2GLAPOLBGAATSHR | |
| SCHEMBL11798096 | 0.82 | NR1H2 (0.50) | NR1H2GLAPOLBGAATSHR | |
| SCHEMBL374610 | 0.80 | NR1H2 (0.51) | NR1H2GLAPOLBGAATSHR | |
| SCHEMBL30401867 | 0.80 | NR1H2 (0.51) | NR1H2GLAPOLBGAATSHR | |
| SCHEMBL2795017 | 0.80 | GAA (0.50) | NR1H2GLAPOLBGAATSHR | |
| SCHEMBL20568125 | 0.80 | NR1H2 (0.49) | NR1H2GLAPOLBGAATSHR | |
| SCHEMBL498104 | 0.79 | S1PR1 (0.50) | NR1H2GLAPOLBGAATSHR | |
| SCHEMBL22300570 | 0.79 | NOS1 (0.46) | NOS1SLC6A4MPONOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609656-B2 | Heteroarylphenylurea derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-12-17 | — | — | US | disclosed |
| US-20080119466-A1 | Heteroarylphenylurea Derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080119466-A1 | Heteroarylphenylurea Derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080119466-A1 | Heteroarylphenylurea Derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1724258-A1 | HETEROARYLPHENYLUREA DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119466-A1 | Heteroarylphenylurea Derivative | CHRM1, CBR3, CHRM2 | NR1H2 421/4885GLA 3615/4885POLB 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.